Strata Skin Sciences (formerly MELA Sciences, Inc.) is an American medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| SSKN | STRATA Skin Sciences, Inc. | 2026-04-02 15:00:00 | 0.19 | -0.1 | -34.48 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SSKN | 0001051514 | STRATA Skin Sciences, Inc. | US86272A3059 | 529900JXBTG5OB59PM04 | 133986004 | OTC | 3841 | Surgical & Medical Instruments & Apparatus | 1231 | DE | 5 WALNUT GROVE DRIVE | HORSHAM | PA | 19044 | UNITED STATES | US | 215-619-3200 | 5 WALNUT GROVE DRIVE, HORSHAM, PA, 19044 | 5 WALNUT GROVE DRIVE, HORSHAM, PA, 19044 | MELA SCIENCES, INC. /NY | — | 1989-01-01 | — | — | https://www.strataskinsciences.com | 3,699,213 | 5,888,199 | 5,888,199 | Strata Skin Sciences (formerly MELA Sciences, Inc.) is an American medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations. | 2026-04-02 21:42:40 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 3,699,213 | -1,259,319 | -25.397 | 5,888,199 | 1,717,038 | 41.1645 |
| 2024 | 4,958,532 | -12,306,224 | -71.2795 | 4,171,161 | -30,889,793 | -88.1031 |
| 2023 | 17,264,756 | -137,425 | -0.7897 | 35,060,954 | 179,501 | 0.5146 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Shmuel Gov | Chief Operating Officer | 2024 | 324,877 | — | — | 120,000 | 25,800 | 470,677 |
| Dolev Rafaeli | Chief Executive Officer, Chairman Of The Board, President | 2024 | 508,882 | — | — | 63,699 | 28,800 | 601,381 |
| Robert Moccia | President, Chief Executive Officer, Director | 2024 | 0 | — | — | 0 | 322,775 | 322,775 |
| Chris Lesovitz | Chief Financial Officer | 2024 | 189,635 | — | — | 71,250 | 16,270 | 277,155 |
| John Gillings | Chief Accounting Officer | 2024 | 82,212 | — | — | 0 | 5,000 | 143,672 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 114 |
| 2024 | 106 |
| 2023 | 99 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 30,696,000 | 33,562,000 | 33,358,000 |
| Cost Of Revenue | 12,815,000 | 14,481,000 | 14,897,000 |
| Gross Profit | 17,881,000 | 19,081,000 | 18,461,000 |
| Research And Development Expenses | 421,000 | 883,000 | 1,317,000 |
| General And Administrative Expenses | 10,184,000 | 11,303,000 | 10,508,000 |
| Operating Expenses | 22,581,000 | 28,336,000 | 27,065,000 |
| Operating Income | -4,700,000 | -9,255,000 | -8,604,000 |
| Net Income | -6,261,000 | -10,086,000 | -10,830,000 |
| Earnings Per Share Basic | -1.35 | -2.65 | -0.31 |
| Earnings Per Share Diluted | -1.35 | -2.65 | -0.31 |
| Weighted Average Shares Outstanding Basic | 4,650,556 | 3,807,186 | 34,920,291 |
| Weighted Average Shares Outstanding Diluted | 4,650,556 | 3,807,186 | 34,920,291 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 7,912,000 | 7,261,000 | 6,784,000 |
| Marketable Securities Current | — | — | — |
| Accounts Receivable | 4,121,000 | 5,253,000 | 4,440,000 |
| Inventories | 2,814,000 | 2,246,000 | 2,673,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 15,600,000 | 16,595,000 | 15,543,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 8,964,000 | 10,061,000 | 11,778,000 |
| Other Assets Non Current | 231,000 | 231,000 | 231,000 |
| Total Assets Non Current | 1,300,000 | 1,300,000 | 800,000 |
| Total Assets | 30,521,000 | 36,157,000 | 42,016,000 |
| Accounts Payable | 2,758,000 | 2,433,000 | 3,343,000 |
| Deferred Revenue | 2,248,000 | 2,241,000 | 2,120,000 |
| Short Term Debt | 15,349,000 | — | — |
| Other Liabilities Current | 6,155,000 | 8,593,000 | 6,306,000 |
| Total Liabilities Current | 26,741,000 | 14,625,000 | 12,174,000 |
| Long Term Debt | 15,349,000 | 15,000,000 | 15,000,000 |
| Other Liabilities Non Current | — | — | — |
| Total Liabilities Non Current | 872,000 | 16,560,000 | 17,154,000 |
| Total Liabilities | 27,613,000 | 31,185,000 | 29,328,000 |
| Common Stock | 6,000 | 4,000 | 35,000 |
| Retained Earnings | -254,405,000 | -248,144,000 | -238,058,000 |
| Accumulated Other Comprehensive Income | — | — | — |
| Total Shareholders Equity | 2,908,000 | 4,972,000 | 12,688,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 4,123,000 | 4,968,000 | 5,553,000 |
| Share Based Compensation Expense | 643,000 | 427,000 | 1,303,000 |
| Other Non Cash Income Expense | -92,000 | -49,000 | -72,000 |
| Change In Accounts Receivable | -1,003,000 | 631,000 | -141,000 |
| Change In Inventories | 288,000 | -572,000 | -689,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | 350,000 | -954,000 | -100,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | -2,794,000 | 188,000 | -519,000 |
| Purchases Of Marketable Securities | — | — | — |
| Sales Of Marketable Securities | — | — | — |
| Acquisition Of Property Plant And Equipment | 1,468,000 | 1,636,000 | 5,019,000 |
| Acquisition Of Business | — | — | 0 |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -1,468,000 | -1,636,000 | -5,019,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 3,579,000 | 1,943,000 | — |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | 0 | 7,000,000 |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 3,579,000 | 1,925,000 | 6,861,000 |
| Change In Cash | -683,000 | 477,000 | 1,323,000 |
| Cash At End Of Period | 7,912,000 | 7,261,000 | 6,784,000 |
| Income Taxes Paid | 9,000 | 23,000 | 22,000 |
| Interest Paid | 1,811,000 | 1,973,000 | 1,415,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -1.35 | -2.65 | -0.31 |
| Price To Earnings Ratio | -0.9333 | -1.0981 | -17.7452 |
| Earnings Growth Rate | -49.0566 | 754.8387 | 93.75 |
| Price Earnings To Growth Ratio | 0.019 | -0.0015 | -0.1893 |
| Book Value Per Share | 0.6253 | 1.306 | 0.3633 |
| Price To Book Ratio | 2.015 | 2.2283 | 15.14 |
| Ebitda | -170,000 | -2,988,000 | -3,615,000 |
| Enterprise Value | 28,645,700.56 | 18,817,911.26 | 200,312,520.791 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | 10.5564 | 3.0169 | 1.1822 |
| Capital Expenditures | 3,026,000 | 3,251,000 | 9,833,000 |
| Free Cash Flow | -5,820,000 | -3,063,000 | -10,352,000 |
| Return On Equity | -2.153 | -2.0286 | -0.8536 |
| One Year Beta | 0.1062 | 0.0107 | -0.0673 |
| Three Year Beta | 0.048 | 0.1849 | 0.3169 |
| Five Year Beta | 0.2308 | 0.5197 | 0.579 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Rubinstein Samuel | Director | 2025-11-18 | 2,168 | A | 5,934 |
| Rubinstein Samuel | Director | 2025-11-18 | 2,832 | A | 8,766 |
| Rubinstein Samuel | Director | 2025-11-17 | 5,500 | D | 12,360 |
| Rubinstein Samuel | Director | 2025-11-17 | 7,200 | D | 5,160 |
| Rubinstein Samuel | Director | 2025-11-17 | 1,394 | D | 3,766 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | 2025-12-31 | 155 | 123 | 1.2602 |
| TWO SIGMA SECURITIES, LLC | 2025-12-31 | 19,017 | 15,093 | 1.26 |
| Creative Planning | 2025-12-31 | 12,620 | 10,016 | 1.26 |
| Tower Research Capital LLC (TRC) | 2025-12-31 | 5,408 | 4,292 | 1.26 |
| Nantahala Capital Management, LLC | 2025-12-31 | 508,935 | 403,917 | 1.26 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| VANGUARD INDEX FUNDS | 2025-12-31 | Institutional Plus Shares | VEMPX | 16,175 | 20,380.5 | 0.0 |
| VANGUARD INDEX FUNDS | 2025-12-31 | ETF Shares | VXF | 16,175 | 20,380.5 | 0.0 |
| VANGUARD INDEX FUNDS | 2025-12-31 | Institutional Shares | VIEIX | 16,175 | 20,380.5 | 0.0 |
| VANGUARD INDEX FUNDS | 2025-12-31 | Admiral Shares | VEXAX | 16,175 | 20,380.5 | 0.0 |
| VANGUARD INDEX FUNDS | 2025-12-31 | Investor Shares | VEXMX | 16,175 | 20,380.5 | 0.0 |